Advancing Efficacious MASH Therapeutics in the Evolving Metabolic Landscape

Driven by a surging pipeline, the MASH therapeutic landscape is radically transforming as more drugs reach clinical trials. While Madrigal's Rezdiffra marked a groundbreaking first approval, it also highlighted the vast scope for further, more comprehensive, patient-centered solutions. This is a pivotal moment to unlock unparalleled potential in conquering this widespread disease.

The 9th MASH Drug Development Summit was the essential forum for pharmaceutical giants and innovative biotechs dedicated to accelerating efficacious therapies for diverse patient populations. At the 2025 summit, we dove deep into the game-changing potential of novel mechanisms of action, advanced biomarker integration, and strategic combination and sequential therapy regimens. Attendees heard from titans such as Eli Lilly, AstraZeneca, Pfizer, and Takeda, alongside innovative biotechs such as Madrigal, Akero Therapeutics, 89 Bio, and more. They learned of the groundbreaking research and strategies focused on effective treatments through varied mechanisms and cell-targeting, accurate non-invasive biomarkers, patient-centered trial designs, and the profound potential of GLP-1s. The pressure remains on to develop best-in-class treatments that transform patient lives.

This summit was the pivotal opportunity to network with 60+ leading MASH scientists and drug development experts, forge crucial collaborations, and be part of the solution!